Covid-19 roundup: Pfiz­er, BioN­Tech set new pro­duc­tion quo­ta for vac­cine at 2B dos­es in 2021; New da­ta show IL-6 in­hibitor could be ef­fec­tive treat­ment af­ter all

Pfiz­er and BioN­Tech are well on their way to a glob­al roll­out of their mR­NA-based Covid-19 vac­cine, BTN162b2. Even with lo­gis­ti­cal chal­lenges ham­per­ing that plan, Ger­many’s BioN­Tech is plan­ning a vast ex­pan­sion of its pro­duc­tion ca­pac­i­ty in the com­ing year.

BioN­Tech plans to churn out more than 2 bil­lion dos­es of BNT162b2 in 2021, far out­pac­ing the 1 bil­lion dos­es tied up in sup­ply com­mit­ment around the globe, the com­pa­ny said in a vir­tu­al pre­sen­ta­tion at the vir­tu­al JP Mor­gan Health­care Con­fer­ence.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.